论文部分内容阅读
目的:探讨检测吲哚胺2,3-双加氧酶(IDO)在良、恶性卵巢肿瘤组织和卵巢癌细胞株中的表达及临床意义。方法:应用荧光定量PCR技术检测32例恶性卵巢上皮性肿瘤组织、8例交界性卵巢上皮性肿瘤组织、12例良性卵巢上皮性肿瘤组织和卵巢癌细胞株SKOV3及HO-8910中IDO的mRNA表达情况,检测肿瘤组织中Foxp3的mRNA表达情况。结果:IDO在卵巢恶性肿瘤中相对表达为(11.21±6.43),明显高于卵巢良性肿瘤(4.17±2.25),差异有统计学意义(P<0.05);IDO的表达与组织学分级和淋巴结转移相关(P<0.05);IDO在卵巢癌细胞株的水平为(3.25±2.61),低于恶性卵巢肿瘤组织中表达水平,差异有统计学意义(P<0.05);肿瘤组织中IDO和Foxp3的表达具有明显相关性(P<0.05)。结论:IDO在恶性上皮性卵巢肿瘤患者中表达增高,IDO表达水平与恶性卵巢肿瘤的分级及淋巴转移密切相关。
Objective: To investigate the expression of indoleamine 2,3-dioxygenase (IDO) in benign and malignant ovarian tumor and ovarian cancer cell lines and its clinical significance. Methods: The mRNA expression of IDO in 32 cases of malignant ovarian epithelial tumor, 8 cases of borderline ovarian epithelial tumor, 12 cases of benign ovarian epithelial tumor and ovarian cancer cell lines SKOV3 and HO-8910 were detected by real-time fluorescence quantitative PCR Cases, detection of tumor tissue Foxp3 mRNA expression. Results: The relative expression of IDO in ovary malignant tumors was (11.21 ± 6.43), which was significantly higher than that in benign ovarian tumors (4.17 ± 2.25), the difference was statistically significant (P <0.05). The expression of IDO was correlated with histological grade and lymph node metastasis (P <0.05). The level of IDO in ovarian cancer cell lines was (3.25 ± 2.61), which was lower than that in malignant ovarian tumor tissues (P <0.05). IDO and Foxp3 Expression was significantly correlated (P <0.05). Conclusion: The expression of IDO is increased in patients with malignant ovarian tumors. The expression of IDO is closely related to the grade of malignant ovarian tumor and lymphatic metastasis.